Epithelial ovarian cancer: Prevention, diagnosis, and treatment

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Ca

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3322/canjclin.49.5.297PMID 11198956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers

  2010cited by this paper
• Phase II trial of zeniplatin (CL 286 558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy

  2005cited by this paper
• Cancer statistics, 1999

  1999cited by this paper
• Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

  1998cited by this paper
• Molecular genetics of hereditary ovarian cancer.

  1998cited by this paper
• Update of the NCCN ovarian cancer practice guidelines

  1997cited by this paper
• Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2

  1997cited by this paper
• Etiology, natural history, management and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): genetic counseling implications.

  1997cited by this paper
• Topotecan in platinum- and paclitaxel-resistant ovarian cancer.

  1997cited by this paper
• Update of the NCCN ovarian cancer practice guidelines.

  1997cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

  1997cited by this paper
• Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium.

  1997cited by this paper
• Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.

  1996cited by this paper
• Laparoscopic management of suspicious adnexal masses.

  1996cited by this paper
• Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.

  1996cited by this paper
• Postmenopausal adnexal cysts: how clinical management has evolved.

  1996cited by this paper
• Genetic counseling in hereditary nonpolyposis colorectal cancer.

  1996cited by this paper
• Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

  1996cited by this paper
• A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

  1996cited by this paper
• Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses.

  1996cited by this paper
• An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.

  1995cited by this paper
• Cancer statistics, 1995

  1995cited by this paper
• Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

  1995cited by this paper
• Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.

  1995cited by this paper
• Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection

  1995cited by this paper
• Cytoreductive surgery in advanced epithelial cancer of the ovary: The impact of aortic and pelvic lymphadenectomy

  1995cited by this paper
• A Phase II Trial of Edatrexate in Previously Treated Ovarian Cancer: A Gynecologic Oncology Group Study

  1995cited by this paper
• A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.

  1995cited by this paper
• Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium.

  1995cited by this paper
• High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.

  1995cited by this paper
• Chemotherapy in advanced ovarian carcinoma: Current standards of care based on randomized trials

  1995cited by this paper
• Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)

  1995cited by this paper
• Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.

  1995cited by this paper
• The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

  1995cited by this paper
• Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

  1995cited by this paper
• Prophylactic oophorectomy in inherited breast/ovarian cancer families.

  1995cited by this paper
• A Phase II Study of Fazarabine in Patients with Advanced Ovarian Cancer A Gynecologic Oncology Group Study

  1995cited by this paper
• Epithelial ovarian carcinoma: principles of primary surgery.

  1994cited by this paper
• Radiotherapy in early ovarian cancer.

  1994cited by this paper
• The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

  1994cited by this paper
• Ovarian cancer screening in asymptomatic postmenopausal women.

  1994cited by this paper
• Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.

  1994cited by this paper
• Secondary cytoreductive surgery for ovarian cancer.

  1994cited by this paper
• Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.

  1994cited by this paper
• Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.

  1994cited by this paper
• Hereditary and familial ovarian cancer in southern ontario

  1994cited by this paper
• Primary chemotherapy of epithelial ovarian carcinoma.

  1994cited by this paper
• Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

  1994cited by this paper
• Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

  1994cited by this paper
• Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

  1994cited by this paper
• Cancer of the ovary.

  1994cited by this paper
• Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

  1994cited by this paper
• The current status of ultrasound and color Doppler imaging in screening for ovarian cancer.

  1994cited by this paper
• Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.

  1994cited by this paper
• Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study.

  1993cited by this paper
• Extracolonic cancer in hereditary nonpolyposis colorectal cancer

  1993cited by this paper
• A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

  1993cited by this paper
• Hexamethylmelamine as second‐line therapy in platin‐resistant ovarian cancer

  1993cited by this paper
• Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer.

  1993cited by this paper
• Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.

  1993cited by this paper
• Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

  1993cited by this paper
• A Phase II Trial of Didemnin B (NSC #335319) in Patients with Previously Treated Epithelial Ovarian Cancer A Gynecologic Oncology Group Study

  1993cited by this paper
• Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study

  1993cited by this paper
• Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

  1993cited by this paper
• Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry

  1993cited by this paper
• Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging.

  1993cited by this paper
• Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991.

  1993cited by this paper
• Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five‐year cancer registry review

  1992cited by this paper
• Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

  1992cited by this paper
• Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging.

  1992cited by this paper
• The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.

  1992cited by this paper
• Hereditary Ovarian Cancer: A Clinicopathological Study

  1992cited by this paper
• Differentiating Malignant From Benign Ovarian Tumors With Transvaginal Color Flow Imaging

  1992cited by this paper
• Early atnniocentesis: alphafetoprotein levels in amniotic fluid, extraembryonic coelomic fluid and maternal serum between 8 and 13 weeks

  1992cited by this paper
• Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.

  1992cited by this paper
• Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

  1992cited by this paper
• Ovarian cancer, Part II: Treatment.

  1992cited by this paper
• Should women with familial ovarian cancer undergo prophylactic oophorectomy?

  1992cited by this paper
• Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.

  1992cited by this paper
• Radical surgical procedure improves survival time in patients with recurrent ovarian cancer

  1992cited by this paper
• Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer.

  1991cited by this paper
• Hereditary ovarian cancer. Pedigree studies, Part II.

  1991cited by this paper
• Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

  1991cited by this paper
• Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors.

  1991cited by this paper
• Hereditary ovarian cancer: Heterogeneity in age at diagnosis

  1991cited by this paper
• Genetic epidemiology of ovarian cancer: segregation analysis

  1991cited by this paper
• Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.

  1991cited by this paper
• Hereditary ovarian cancer. Heterogeneity in age at diagnosis

  1991cited by this paper
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

  1991cited by this paper
• Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis

  1991cited by this paper
• Phase II trial of trimelamol in refractory ovarian cancer.

  1991cited by this paper
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

  1991cited by this paper
• Modified posterior exenteration for ovarian cancer.

  1991cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper

• Global, regional, and national burden of ovarian cancer due to high BMI, 1990-2021 and projections to 2050: a systematic analysis based on the global burden of disease 2021 study.

  2026cites this paper
• In vitro analysis of the molecular mechanisms of ursolic acid against ovarian cancer

  2025cites this paper
• N6-methyadenosine modified KREMEN2 promotes tumorigenesis and malignant progression of high grade serous ovarian cancer.

  2024cites this paper
• Survey of AI-driven techniques for ovarian cancer detection: state-of-the-art methods and open challenges

  2024cites this paper
• Prognostic Signi fi cance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma

  2022cites this paper
• Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma

  2022cites this paper
• Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

  2021cites this paper
• Application in Gene Editing in Ovarian Cancer Therapy

  2021cites this paper
• TIPE1 impairs ovarian tumor growth by promoting caspase-dependent apoptosis

  2020cites this paper
• Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.

  2019cites this paper
• High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome

  2019cites this paper
• Effect of paclitaxel-cisplatin chemotherapy towards hemoglobin, platelet, and leukocyte levels in epithelial ovarian cancer patients

  2019influential citation
• THE RELATION BETWEEN CA 125, CECT ABDOMEN & PELVIS AND HISTOPATHOLOGICAL FEATURES IN OVARIAN NEOPLASMS

  2019cites this paper
• Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.

  2019cites this paper
• Novel strategy of ovarian cancer implantation: Pre‐invasive growth of fibrin‐anchored cells with neovascularization

  2019cites this paper
• Serum CA 125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer

  2019cites this paper
• Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer

  2019cites this paper
• Ovarian Cancer Stem Cell Heterogeneity.

  2019cites this paper
• Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.

  2018cites this paper
• Evaluation of Vav3.1 as prognostic marker in endometrial cancer

  2018cites this paper
• Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia

  2018cites this paper
• Efficacy of morphological indexing of ovarian tumor: preoperative determination of risk of malignancy

  2017cites this paper
• Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer

  2017cites this paper
• Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium

  2017cites this paper
• Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp

  2017cites this paper
• Efficacy of ChemoID® guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: Case study

  2017cites this paper
• Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy.

  2016cites this paper
• Etude de l’impact de la vitronectine et de la fibronectine ascitiques sur la récidive des carcinomes ovariens

  2016cites this paper
• Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions

  2016cites this paper
• SIAH 2 expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer

  2016cites this paper
• The Potential Protective Effect of Stem Cell Enhancer on Chronic Bisphenol-A Treated Female Albino Rats

  2016cites this paper
• Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis

  2016cites this paper
• Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.

  2016cites this paper
• Integrated glycomic analysis of ovarian cancer side population cells

  2016cites this paper
• Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis

  2016cites this paper
• Alternative tumor markers in the diagnosis of ovarian cancer.

  2016cites this paper
• Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

  2015cites this paper
• Ovarian cancer ascites enhance the migration of patient‐derived peritoneal mesothelial cells via cMet pathway through HGF‐dependent and ‐independent mechanisms

  2015cites this paper
• Review Article The role of the fallopian tube in ovarian serous carcinogenesis: biologic mechanisms and clinical impacts

  2015cites this paper
• Potential of Terpenoid Bioactive Compound Isolated from Papua Ant Nest as an Alternative Ovarian Cancer Treatment

  2015cites this paper
• Terpenoid Bioactive Compound Isolated from Papua Ant Nest Induces the Apoptosis of Human Ovarian Cell Lines ( SKOV-3 ) and Increasing Caspase-9 Activity

  2015influential citation
• The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer.

  2014cites this paper
• Role of malignant ascites on human mesothelial cells and their gene expression profiles

  2014cites this paper
• (E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway

  2014cites this paper
• Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway

  2014cites this paper
• TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction.

  2014cites this paper
• Role of Preventive Oncology in Ovarian Cancer.

  2014cites this paper
• (E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway

  2014cites this paper
• Estudio comparativo entre cirugía primaria y cirugía de intervalo en el estadio iiic del cáncer de ovario

  2014cites this paper
• Ovarian cancer biomarkers: current state and future implications from high-throughput technologies.

  2014cites this paper
• Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer.

  2013cites this paper
• S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

  2013cites this paper
• Characterization of Kallikrein 6 N-glycosylation Patterns and Identification of Sialylated Glycoproteins in Ovarian Cancer

  2013cites this paper
• Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer

  2013cites this paper
• Clinicopathological Significance and Prognostic Value of DNA Methyltransferase 1, 3a, and 3b Expressions in Sporadic Epithelial Ovarian Cancer

  2012cites this paper
• Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2

  2012cites this paper
• Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis

  2012cites this paper
• Effect of Bee Venom Death Receptor Dependent Apoptosis and JAK2/STAT3 Pathway in the Ovarian Cancer

  2012cites this paper
• Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.

  2012cites this paper
• Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

  2012cites this paper
• Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas: Correlation With Histology, Serum CA-125 Assay, and Conventional Radiological Modalities

  2012cites this paper
• Pharmacological and Toxicological Advances in PPAR-Related Medicines

  2012cites this paper
• Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis

  2012cites this paper
• Profiling of cytokines in human epithelial ovarian cancer ascites.

  2012cites this paper
• The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

  2012cites this paper
• Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis

  2012cites this paper
• Targeted ovarian cancer treatment: the TRAILs of resistance.

  2012cites this paper
• Immunohistochemical evaluation of a new epithelial antigen, BER-EP4 in ovarian cancer: a propos of 62 cases.

  2012cites this paper
• Effect of Snake Venom on Cancer Growth through Induction of Apoptosis via Down Regulation of NF-${\kappa}B$ and STAT3 in the PA-1, Ovarian Cancer Cells

  2012cites this paper
• The use of Thrombospondin-1 Mimetic Peptides for the Treatment of Epithelial Ovarian Cancer

  2012cites this paper
• Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts

  2012cites this paper
• The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

  2011cites this paper
• Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

  2011cites this paper
• NFKB1 Insertion/Deletion Promoter Polymorphism Increases the Risk of Advanced Ovarian Cancer in a Chinese Population

  2011cites this paper
• STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.

  2011cites this paper
• Conditionally Replicating Adenovirus Expressing TIMP2 Increases Survival in a Mouse Model of Disseminated Ovarian Cancer

  2011cites this paper
• Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

  2011cites this paper
• MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.

  2011cites this paper
• Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines

  2011cites this paper
• HE4 in ovarian cancer: from discovery to clinical application.

  2011cites this paper
• Evaluation of active hexose correlated compound (AHCC) in combination with pegylated liposomal doxorubicin for treatment of ovarian cancer

  2011cites this paper
• Pathogenesis of Ovarian Cancer

  2011cites this paper
• Assessing Pelvic Cancer Risk and Intercepting Early Malignancy

  2011cites this paper
• Inhibition of the Src Oncogene: Therapeutic Potential in Ovarian Carcinoma

  2011cites this paper
• Univerzita Palackého v Olomouci

  2011cites this paper
• Symptoms and diagnostic delay in ovarian cancer: A summary of the literature

  2010influential citation
• Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer.

  2010cites this paper
• Current state of biomarker development for clinical application in epithelial ovarian cancer.

  2010cites this paper
• Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.

  2010cites this paper
• Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway

  2010cites this paper
• Discovery of novel ovarian cancer biomarkers via proteomics and mass spectrometry.

  2010cites this paper
• p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.

  2010cites this paper
• EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

  2009cites this paper
• Functional significance of VEGFR‐2 on ovarian cancer cells

  2009cites this paper
• CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

  2009cites this paper
• A model of CAM use by women with female-specific cancers.

  2008cites this paper
• Mechanisms of Cables 1 gene inactivation in human ovarian cancer development

  2008cites this paper
• The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.

  2008cites this paper
• Evaluation of Ovarian Tumors by Proton Magnetic Resonance Spectroscopy at Three Tesla

  2008cites this paper
• National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

  2008cites this paper